BenevolentAI : H1 2024 results contained no surprises. Out-licensing of BEN-8744 in the spotlight
>Cost-cutting plan paying off - BenevolentAI released its H1 2024 results yesterday. Our key takeaways are as follows: 1/ revenues down 46% to £ 2.8m, marked both by lower revenues from the AstraZeneca collaboration and including receipts from the recent Merck collaboration, which are expected to grow over the H2 2024-2026 period, 2/ a 39% reduction in R&D expenditure to -£ 19.5m and 3/ a reduction in SG&A expenditure of 21% to -£ 10.3m, in line with the cost-cutting ...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.